ABSTRACT Background: The New Zealand population has both marginal selenium status and mild iodine deficiency. Adequate intakes of iodine and selenium are required for optimal thyroid function. Objective: The aim of the study was to determine whether low selenium and iodine status compromises thyroid function in an older New Zealand population. Design: We investigated the effects of selenium and iodine supplementation in a double-blind, randomized, placebo-controlled trial in 100 Dunedin volunteers aged 60-80 y. Participants received 100 lg Se/d as L-selenomethionine, 80 lg I, 100 lg Se + 80 lg I, or placebo for 3 mo. Thyroid-stimulating hormone (TSH), free triiodothyronine (T 3 ), free thyroxine (T 4 ), thyroglobulin, plasma selenium, whole-blood glutathione peroxidase (GPx) activity, and urinary iodine concentrations (UICs) were measured. Results: Plasma selenium (P , 0.0001) and whole-blood GPx activity (P,0.0001) increased from baseline to week 12 in the selenium and selenium plus iodine groups in comparison with the placebo group. Median UIC at baseline was 48 lg/L (interquartile range: 31-79 lg/L), which is indicative of moderate iodine deficiency. UIC increased in the iodine and selenium plus iodine groups and was significant only for the iodine group (P = 0.0014). Thyroglobulin concentration decreased by 24% and 13% of baseline in the iodine and selenium plus iodine groups in comparison with the placebo group (P = 0.009 and P = 0.108, respectively). No significant treatment effects were found for TSH, free T 3 , free T 4 , or ratio of T 3 to T 4 . Conclusions: Additional selenium improved GPx activity but not the thyroid hormone status of older New Zealanders. Iodine supplementation alleviated the moderate iodine deficiency and reduced elevated thyroglobulin concentrations. No synergistic action of selenium and iodine was observed. The trial was registered at www. anzctr.org.au/registry/ as ACTRN012605000368639.
INTRODUCTION
Adequate intakes of both iodine and selenium are required for optimal thyroid function (1) (2) (3) . Iodine is an essential component of the thyroid hormones thyroxine (T 4 ) and triiodothyronine (T 3 ), and deficiency will impair synthesis of these hormones. Selenium is essential for the biosynthesis and function of the iodothyronine deiodinases that control the conversion of T 4 to T 3. In addition, selenium-dependent glutathione peroxidases (GPxs) are implicated in the protection against oxidative damage to the thyroid gland (1) (2) (3) (4) . Selenium deficiency will decrease conversion of T 4 to T 3 , and it increases oxidant stress on the thyroid gland as a result of reduced GPx activity (2, 4) . Both selenium and iodine deficiencies may exacerbate the effects of individual deficiencies such that selenium deficiency, in the presence of severe iodine deficiency, with the associated hyperstimulation of the thyroid and increased H 2 O 2 production, results in reduced GPx activity and subsequent reduction in the clearance of H 2 O 2 (1, 4) .
The interaction between selenium and iodine status is of particular interest in New Zealand where intakes of both trace elements are relatively low (5) . New Zealanders have experienced a return to mild-moderate iodine deficiency, with elevated serum thyroglobulin and enlarged thyroid glands (6) (7) (8) . Although selenium status has increased, intakes for many New Zealanders are still insufficient for maximal GPx activity (8) (9) (10) . In a 1995 study, selenium supplementation resulted in a small but significant decrease in plasma T 4 and an increase in the ratio of T 3 to T 4 (T 3 :T 4 ) (9); however, in later studies, changes were small and not significant (11) .
Older people are particularly vulnerable to suboptimal selenium and iodine status as a result of imbalanced nutrition (12, 13) . In a study of 103 New Zealand women aged 70-80 y, selenium intake was 34 lg/d and plasma selenium concentration was 0.86 lmol/L, significantly lower than those of younger adult women assessed at the same time (14) . The iodine status of older New Zealanders has not been determined, but it is expected to be low along with the rest of the adult population (8) . In addition, the elderly are at increased risk of thyroid insufficiency, and age-related changes in thyroid-stimulating hormone (TSH), T 4 , and T 3 have been observed (15) . The elderly are a growing segment of the population, and impaired thyroid function as a result of low selenium and iodine status may have consequences on health and well-being which will strain health care resources.
We hypothesized that current selenium and iodine intakes of older New Zealanders might be inadequate for optimal conversion of T 4 to T 3 . A recent study by Rayman et al (16) did not find any effect of selenium intervention on thyroid function in British elderly residents with similar selenium status, but they did not assess iodine status, which they reported to be adequate, nor did they supplement with iodine in addition to selenium. Similarly, Combs et al (17) did not find an effect of selenium supplementation alone on thyroid function in US residents with adequate selenium status. The aim of our study was to investigate the effect of selenium and iodine supplementation separately and together on selenium and iodine status and thyroid function.
SUBJECTS AND METHODS
A randomized controlled trial was carried out with older male and female residents of Dunedin in the South Island of New Zealand from August to November 2005. Participants were aged between 60 and 80 y; were noninstitutionalized, were free from serious medical illness such as cancer, diabetes, or cardiovascular disease; were not using medications for thyroid function or with any known thyroid problems, and were not taking multivitaminmultimineral or other dietary supplements that contained selenium or iodine. Subjects were recruited by advertisements in regional and community newspapers, club and church newsletters, on notice boards in retirement villages, supermarkets, hospitals, and leisure centers; by letters sent to participants in a previous study conducted in the Department of Human Nutrition; and by visits and presentations to various senior citizen organizations. All participants gave their informed consent, and the Ethics Committee of the University of Otago, Dunedin, New Zealand, approved the protocol.
Study design
Potential participants were screened by telephone with the use of a brief questionnaire that included questions on age, health, and inclusion criteria. Respondents who met the inclusion criteria were mailed information sheets and consent forms, and after consent they were randomly assigned into treatment groups. Block randomization with stratification by sex was used to assign 76 participants into 1 of 3 treatment groups (November 2005): 100 lg Se (n = 26), 80 lg I (n = 25), and placebo (n = 25). The randomization scheme was generated by using the website Randomization.com (www.randomization.com). The fourth group, 100 lg Se + 80 lg I (n = 26), was part of another earlier randomization of 4 groups of subjects (August 2005 ). An error in the manufacturer of some supplements used for the first randomization and intervention resulted in very high intakes of iodine for participants in 3 of the groups, and it was necessary to terminate their intervention. No significant differences were observed in baseline measures of selenium, iodine, or thyroid hormone status of the final 4 groups ( Table 1) .
A decrease of 2 pmol/L in serum-free T 4 concentration in the treatment groups was considered to be a clinically important change. To have a power of 90% to detect a true difference of 2 pmol/L in serum-free T 4 between a treatment group and the control group, a sample size of 22 people per group is required. This calculation is based on the assumption that the SD is 2 pmol/L. We assumed a 2-sided statistical test and a 5% level of significance. Assuming 15% attrition over the study duration, 25 people per group were required.
A staff member not involved with the recruitment of participants for the study was in charge of the randomization list and kept the list private, only revealing the treatment allocation for a participant after receiving the information that the patient was eligible for the study and had consented to take part. The staff member responsible for assigning participants to their groups had no direct contact with the patients; hence allocation was independent of recruitment (ie, the sequence was concealed until interventions were assigned). The participants, investigators administering the interventions, and investigators assessing the outcomes of the intervention were blinded to the treatment assignment. Participants completed a brief questionnaire that included questions on demographics, dietary habits, supplement and medication use, smoking habits, consumption of foods high in selenium or iodine such as seafood and Brazil nuts, and selfreported health status. Fasting blood samples were collected at baseline and at weeks 2, 4, 8, and 12, and casual morning urine samples were collected at baseline and week 12. Duplicate height and weight measurements were made at baseline for calculation of body mass index (BMI; in kg/m 2 ).
Treatments
Tablets, identical in size, shape, and color, were produced by Alaron Products (Port Nelson, New Zealand). Iodine tablets contained potassium iodate, and selenium tablets contained L-selenomethionine. One batch only of each supplement was produced. Ten tablets were randomly selected from each group and analyzed for iodine and selenium content by Hill Laboratories Ltd (Hamilton, New Zealand) with the use of inductively coupled plasma mass spectrometry with a detection limit of 0.01 lg Se/tablet and 0.02 lg I/tablet, respectively. Placebo tablets contained ,0.01 lg selenium or iodine per tablet, selenium tablets contained a median of 108 lg Se [interquartile range (IQR): 100-110 lg Se] with negligible iodine; iodine tablets contained negligible selenium and a median of 79 lg I (IQR: 76-82 lg I); and selenium plus iodine tablets contained 94 lg Se (IQR: 88-99 lg Se) and 80 lg I (IQR: 71-103 lg I) per tablet.
Participants consumed 1 tablet daily for 12 wk; they were encouraged to maintain their normal diets and to avoid supplements that contained selenium or iodine for the study duration. Compliance was monitored by completion of a daily checklist and from the number of tablets returned at study conclusion.
Sample collection
Blood was collected in EDTA-coated tubes (Becton Dickinson, Franklin Lakes, NJ) for separation of whole blood and plasma and additive free evacuated tubes for serum. Samples were kept on ice and centrifuged within 3 h of collection. Aliquots of whole blood, plasma, and serum were stored at 280°C until analysis. Casual morning (between 0730 and 0930) urine samples were collected in clean, plastic specimen containers and stored at -20°C until analysis.
Analytic methods
Plasma selenium concentrations were determined in duplicate by graphite furnace Atomic Absorption Spectroscopy with Zeeman background correction (AA-800; Perkin-Elmer Corp, Norwalk, CT) by a modification of the method of Jacobson and Lockitch (18) . Accuracy was assessed by analysis of certified reference materials (CRMs) with each batch; Seronorm Reference Serum (batch no. JL4409; Laboratories of SERO AS, Billingstad, Norway), with a certified selenium concentration of 0.92 lmol Se/L (95% CI: 0.84, 1.00 lmol Se/L), gave a mean (6SD) concentration of 0.88 6 0.04 lmol/L (CV: 4.9%; n = 45). Analysis of Utak Reference Plasma (batch no. 66816, lot 7081; UTAK Laboratories Inc, Valencia, CA), with a certified selenium concentration of 1.52 lmol Se/L (95% CI: 1.14, 1.90 lmol Se/L), gave a mean of 1.39 6 0.09 lmol Se/L (CV: 6.2%; n = 45).
GPx activity was measured in whole blood with the use of RANSEL kits (no. RS 505, 506; Randox Laboratories Ltd, Antrim, United Kingdom) and automated on a Cobas Fara autoanalyser (Hoffman-La Roche, Basel, Switzerland). Whole-blood GPx was assayed as a measure of erythrocyte GPx activity, which has been shown previously by us to constitute 95% of whole blood activity with the use of this assay method (19) . Because no RANSEL controls were available at the time, pooled samples of whole blood were analyzed with each batch and gave a mean activity of 45.5 6 2.8 U/g hemoglobin (CV: 6.2%; n = 196).
Urinary iodine concentration ( Serum thyroglobulin concentrations were determined by Endolab, Christchurch Hospital, (Christchurch, New Zealand). Baseline samples were tested for the presence of thyroglobulin antibodies because these can interfere with measurement of thyroglobulin by immunologic methods. If the antibody was present at baseline, then the participant's corresponding week 12 sample was not analyzed, and results from this subject were not included in the data analysis. Both thyroglobulin and thyroglobulin antibodies were measured by immunoenzymatic (2-site) assays with chemiluminescent detection with the use of an Access 2 analyzer (Beckman Coulter Inc, Fullerton, CA), with a lower limit of detection of 0.1 ng thyroglobulin /mL and 2.2 kIU thyroglobulin antibody/L, respectively. External quality control samples used were CRM 457 thyroglobulin standard (European Community Bureau of Reference) and the thyroglobulin antibody WHO 65/93 International standard. Interassay CVs for thyroglobulin were 5.1% at 35.1 lg/L and 6.9% at 288 lg/L (n = 46), and for thyroglobulin antibody, 18% at 4.5 kIU/L and 7.7% at 307 kIU/L (n = 48). For all analytic methods, all samples from each participant were analyzed in the same batch.
Statistical analysis
All statistical analyses were conducted with the use of SAS 9.1.3 (SAS Institute Inc, Cary, NC) or SPSS Version 14.0 for SELENIUM, IODINE SUPPLEMENTS, AND THYROID FUNCTION Windows (SPSS Inc, Chicago, IL). Statistical significance was assessed at P , 0.05.
Descriptive statistics are presented for all baseline characteristics. Although it is not considered good practice in a randomized control trial to test for baseline differences between groups, because the process of randomization means any differences will simply be due to chance (21, 22) , we chose to test for baseline differences as our recruitment was undertaken in 2 stages. Positively skewed data were described with the use of median (IQR). Categorical baseline characteristics were described with number of participants (%). Differences between groups of normally distributed variables were tested with the use of one-factor analysis of variance for continuous data and chisquared test for categorical data. Differences between groups of skewed variables were tested with the Kruskal-Wallis test. Associations between biological indexes of selenium (plasma selenium, whole-blood GPx), iodine (UIC), and thyroid status (free T 4 , free T 3 , T 3 :T 4 , TSH, thyroglobulin) at baseline were assessed with the use of Pearson's correlation coefficient. Initially, univariate analyses with the variables plasma selenium and UIC were performed to investigate factors associated with these outcomes at baseline. The factors considered were age, sex, BMI, the 2001 New Zealand Index of Deprivation (NZDep2001; an index based on an individual's residential address) (23), smoking status, and medication and supplement use. Multiple linear regression was used to determine which factors were independently associated with the outcome variables.
For the intervention study, linear mixed effects regression models, including both fixed and random effects, were used to examine the effect of treatments on the continuous outcomes. Positively skewed data were log-transformed before the statistical analysis. The random effects allowed for possible correlation between repeated measures over time within a subject. This was necessary for our data because plasma selenium, wholeblood GPx, TSH, free T 4 , and free T 3 were measured at 5 time points (weeks 0, 2, 4, 8, and 12), and thyroglobulin and UIC were measured at 2 time points (weeks 0 and 12). The models contained treatment group, time, and the treatment-by-time interaction as fixed effects and subject as the random effect. The participant characteristics of age, sex, BMI, medication and supplement use, and individual baseline plasma selenium concentrations were also included in the model because these were potential confounders. The primary measure of interest was the change in mean response from baseline to week 12 for the outcome variables. Pairwise comparisons were made between groups only if the treatment-by-time interaction was significant (P , 0.05).
Random coefficients or mixed means models were used to analyze the data. The choice of model was based on the Akaike Information Criterion values for the models. In a means model, the pattern of covariance between repeated measurements is modeled. However, no structure is imposed on the mean response trend over time (time is a categorical variable in the model); hence, the time ordering of the observations is ignored (24) . In a random coefficients model, it is assumed that there is a linear relation between the outcome variable and time. The random coefficients model allows the slopes and intercepts to vary randomly between the study subjects; hence, a separate regression line is fitted for each subject (25) . If there was a nonlinear relation between the outcome variable and time, we investigated the use of a quadratic curve or a linear spline. Outcome variables were log-transformed if it improved the model fit. The mixed models were fitted with the use of SAS PROC MIXED (SAS Institute Inc).
A 2-factor analysis was not considered, because our main focus was to compare the effect of selenium and iodine together with the separate effects of selenium alone, iodine alone, and the placebo on the outcomes of interest. This would not be possible if both selenium groups or both iodine groups were combined. We did not consider a post hoc 2-factor analysis appropriate, because this would not have strengthened the effects of treatments on serum T 3 or T 4 concentrations, the primary outcomes of interest.
RESULTS
Of the 102 participants initially randomly assigned to treatment groups, 1 participant was excluded from all analyses because her test results indicated thyroid disease, 1 participant did not attend the baseline clinic, leaving 100 participants for whom baseline characteristics are reported (Table 1) . By week 12, a further 3 participants had dropped out, leaving 97 participants who completed the trial (23, 25, 24, 25 in the placebo, selenium, iodine, and selenium plus iodine groups, respectively). A further 9 participants did not provide urine samples for reasons that included difficulty in passing urine or were unwilling to provide a sample. Compliance with supplement use was excellent with 90% of all participants consuming all supplements and 10% consuming between 97% and 99% of their supplements.
Baseline selenium, iodine, and thyroid hormone status Mean ages and BMIs of participants in the 4 groups were similar, and no significant differences were observed among the treatment groups at baseline for measures of selenium, iodine, or thyroid hormone concentrations (Table 1) . Plasma selenium concentrations and whole blood GPx activities at baseline were normally distributed (Table 1) . Univariate analysis of independent factors, including age, sex, BMI, NZDep2001 score, use of medication or supplements, and smoking status showed no significant associations with baseline plasma selenium. Similarly, multiple linear regression showed that these factors explained little of the variation in baseline plasma selenium concentrations (R 2 = 4.7%). A moderate correlation was observed between plasma selenium and whole blood GPx activity at baseline (r = 0.329, P = 0.001).
Urinary iodine concentrations were positively skewed, and baseline data are reported as median ( Table 1 ). The unadjusted median UIC (MUIC) of all participants at baseline was 48 lg/L (IQR: 31-79 lg/L), which is indicative of moderate iodine deficiency (20) . UIC was ,100 lg/L in 83% of participants and ,50 lg/L in 53%. Univariate analysis of factors, including age, sex, BMI, NZDep2001 score, use of medication or supplements, smoking status, and use of iodized salt, showed no significant associations with UIC. Multiple linear regression analysis showed a tendency for participants classified in the highest categories of deprivation (7-10) to have a higher UIC than participants in the lowest categories (1-3) (P = 0.056). However, overall these factors explained little of the variation in UIC (R 2 = 0.063).
Free T 3 concentrations were all within the manufacturer's reference range (2.8-6.8 pmol/L). Two participants had free T 4 concentrations below the manufacturer's reference range (10-23 pmol/L) and 2 had TSH concentrations outside the reference range (0.3-5 mIU/L).
Nine participants had detectable thyroglobulin antibodies, and their thyroglobulin results were excluded from analysis. The median thyroglobulin concentration of 15.8 lg/L (IQR: 10.0-29.2 lg/L) was indicative of mild iodine deficiency (range: 10.0-19.9 lg/L) (26). Four people had thyroglobulin concentrations outside the reference range of 0-58 lg/L, and 37 participants (42%) had thyroglobulin concentrations .20 lg/L. Neither plasma selenium nor whole blood GPx was significantly associated with measures of iodine or thyroid hormone status at baseline.
Effect of selenium and iodine supplementation

Effect on selenium status
The relation between plasma selenium concentration and time was not linear ( Figure 1) ; therefore, plasma selenium was modeled with the use of a linear spline with a knot at week 4 and adjusted for possible confounders. At week 12, unadjusted plasma selenium concentrations had increased by 0%, 82%, 8%, and 79% of baseline values in the placebo, selenium, iodine, and selenium plus iodine groups, respectively. When adjusted for age, sex, BMI, medication use, and supplement use and compared with the placebo group, the overall change was statistically significant for the selenium (0.99 lmol/L; 95% CI: 0.84, 1.14 lmol/L; P , 0.0001) and selenium plus iodine (0.96 lmol/ L; 95% CI: 0.81, 1.16 lmol/L; P , 0.0001) groups but not for the iodine group. Pairwise comparisons between the groups showed that adjusted overall changes in plasma selenium concentrations of both the selenium and selenium plus iodine groups differed significantly from both the iodine and placebo groups (P , 0.0001 for all) but not from each other.
The relation between whole-blood GPx activity and time was linear and modeled with the use of a random coefficients model, similarly adjusted for confounders ( Figure 2) . By week 12 unadjusted changes in whole-blood GPx activity were 0%, 9%, 21%, and 9% of baseline values in the placebo, selenium, iodine, and selenium plus iodine groups, respectively. When adjusted for baseline measures and compared with the placebo group, the overall change was significant in the selenium group (GPx activity of 4.5 U/g; 95% CI: 2.7, 6.2 U/g; P , 0.0001) and the selenium plus iodine group (GPx activity of 5.2 U/g; 95% CI: 3.3, 7.1 U/g; P , 0.0001) but not in the iodine group. Pairwise comparisons between the treatment groups showed that adjusted overall changes in whole-blood GPx activity were significantly greater in the selenium and selenium plus iodine groups than in the iodine group (P , 0.0001 for both) but not from each other.
Effect on iodine and thyroid status
The relations between time and UIC, TSH, thyroglobulin, free T 3 , free T 4 concentrations, and T 3 :T 4 were linear and were modeled with the use of a random coefficient model that adjusted for potential confounders. With the exception of free T 3 and free T 4 , all data were log-transformed, and the geometric mean (95% CI) at baseline and week 12 was reported.
By week 12, UIC (geometric mean) had changed by 27%, 21%, 120%, and 27% of baseline values in the placebo, selenium, iodine, and selenium plus iodine groups, respectively, after adjustment for age, sex, BMI, medication use, and supplement use ( Table 2 ). This change was significant only in the iodine group (P , 0.001). The adjusted mean ratio for the selenium, iodine, and selenium plus iodine groups, respectively, was 6%, 136%, and 37% more than the adjusted mean ratio for the placebo group. This was statistically significant for the FIGURE 1. Mean (6SE) plasma selenium concentrations during daily supplementation for 12 wk with 100 lg Se/d as L-selenomethionine (n), 80 lg I as potassium iodate (:), 100 lg Se + 80 lg I (d), or placebo (¤). A mixed model with a linear spline with a knot at week 4 was used to test for differences between the intervention and placebo groups in the change from baseline to week 4 and the change from week 4 to week 12, with adjustment for age, sex, BMI, medication use, and supplement use. Significant time-bytreatment effects were found (P , 0.0001 for both). The overall change from baseline to week 12 in comparison with the placebo group was significant for the selenium and selenium plus iodine groups (P , 0.0001 for both). 2. Mean (6SE) whole-blood glutathione peroxidase (GPx) activity during daily supplementation for 12 wk with 100 lg Se/d as L-selenomethionine (n), 80 lg I as potassium iodate (:), 100 lg Se + 80 lg I (d), or placebo (¤). Random coefficients model was used to test differences between intervention and placebo groups, with adjustment for age, sex, BMI, baseline plasma selenium, medication use, and supplement use. A significant time-by-treatment effect was found (P , 0.0001). The change in comparison with the placebo group was significant for the selenium and selenium plus iodine groups (P , 0.0001 for both).
iodine group only (P = 0.0014). Pairwise comparisons between all treatment groups showed that the adjusted change in the UIC of the iodine group was significantly greater than that of the selenium group (the adjusted mean ratio for the iodine group was 122% more than the adjusted mean ratio for the selenium group; 95% CI: 35, 265%; P = 0.0019), and there was a trend for the change in the UIC of the iodine group to be greater than the change of the selenium plus iodine group (the adjusted mean ratio for the iodine group was 72% more than the adjusted mean ratio for the selenium plus iodine group; 95% CI: 21, 200%; P = 0.054).
At week 12 median UICs of participants in the 2 iodinesupplemented groups were still indicative of mild iodine deficiency (UIC , 100 lg/L) (26) (68 lg/L; IQR: 41, 131 for the iodine group; 97 lg/L; IQR: 51, 146 for the selenium plus iodine group) . Sixty-eight percent and 52% of participants in the 2 groups had UICs indicative of iodine deficiency. These proportions were smaller than those reported at baseline (88%, 76%, respectively).
Mean thyroglobulin concentrations decreased from baseline to week 12 by 5%, 3%, 27%, and 18% in the placebo, selenium, iodine, and selenium plus iodine groups, respectively, after adjustment for age, sex, BMI, medication use, and supplement use ( Table 3) . The decrease was significant in the iodine (P , 0.0001) and selenium plus iodine (P = 0.0053) groups. After adjustment for the change in the placebo group, the change (24%) in thyroglobulin was significant for the iodine group (P = 0.0009), but the change in the selenium plus iodine group (13%) was no longer significant (P = 0.108). Despite the decrease in thyroglobulin concentrations from baseline, median concentrations in the iodine (12.0 lg/L) and selenium plus iodine (11.6 lg/L) groups at week 12 were still indicative of mild iodine deficiency (26) , although the proportion of people with thyroglobulin concentration . 20 lg/L was lower than that at baseline in the iodine (30% cf 39%) and selenium plus iodine groups (25% cf 33%).
Changes in mean TSH, free T 3 , free T 4 concentrations, and geometric mean T 3 :T 4 with supplementation were not statistically significant, and there were no time-by-treatment interactions ( Table 4) . There was a nonsignificant trend for free T 3 concentration to increase in both the selenium (increase of 0.15 pmol/L; 95% CI: 20.02, 0.31 pmol/L; P = 0.080) and the iodine (0.14 pmol/L; 95% CI: 20.02, 0.30 pmol/L; P = 0.089).
DISCUSSION
Our study is unique in that the effect on thyroid status of supplementation with both selenium and iodine was investigated. Daily supplementation with 100 lg Se for 12 wk did not significantly affect thyroid function in older New Zealanders, 1 Values are unadjusted geometric means; 95% CIs in parentheses. Significant time-by-treatment interaction, P = 0.004 (random-coefficients model). 2 Ratio of geometric means of week 12 relative to baseline, with adjustment for age, sex, BMI, baseline plasma selenium, medication use, and supplement use.
3 Ratio of geometric means of the intervention group (week 12 relative to baseline) relative to the placebo group, with adjustment for age, sex, BMI, baseline plasma selenium, medication use, and supplement use.
4 P , 0.001. 5 P = 0.0014. 1 Values are unadjusted geometric means; 95% CIs in parentheses. Significant time-by-treatment interaction, P = 0.0012 (random-coefficients model). 2 Ratio of geometric means of baseline to week 12, with adjustment for age, sex, BMI, baseline plasma selenium, medication use, and supplement use. 3 Ratio of geometric means of the intervention groups relative to the placebo group, with adjustment for age, sex, BMI, baseline plasma selenium, medication use, and supplement use.
4 P , 0.0001. 5 P = 0.0009. 6 P = 0.0053. despite significant increases in plasma selenium and wholeblood GPx activities. No changes were found for TSH, free T 3 , free T 4 , or thyroglobulin concentrations, apart from a nonsignificant increase in free T 3 (P = 0.080). A recent study of British elderly also did not show an effect of selenium intervention on thyroid hormones, although there was an association between baseline plasma selenium and free T 4 (16) . Similarly, selenium supplementation alone did not affect thyroid hormones in US individuals with more than adequate selenium status, apart from an increase in T 3 concentration in men but not women (17) . One human cross-sectional study has shown an association between selenium and free T 3 , but the relation was no longer significant after controlling for sex and other thyroid hormone variables (27) . An increase in free T 3 concentration with selenium supplementation is biologically plausible; it suggests that deiodinase activity was up-regulated, increasing the conversion of T 4 to T 3 . In our study, there was no concurrent decrease in free T 4 concentration, and the free T 3 :T 4 was unchanged. Furthermore, similar changes were not observed in the selenium plus iodine group; therefore, the clinical significance of this change in free T 3 is questionable. There was no additional beneficial effect of selenium added to iodine in improving thyroid hormone status. Five randomized controlled trials in healthy human adults have shown a decrease in serum T 4 with selenium intervention (9, 11, 28, 29) , although in only 2 were changes statistically significant (9, 29) . Our trial differed from earlier studies in that mean plasma selenium concentration at baseline (1.20 lmol/L) was higher, as was that of elderly British subjects (1.16 lmol/L) (16) and US subjects (1.78 lmol/L) (17), compared with 0.83 lmol/L (9) and 0.81 lmol/L (29) in the 2 earlier trials. In studies of children severely deficient in selenium and iodine (30) or phenylketonuria (31) , when selenium supplementation decreased T 4 concentration, baseline plasma selenium was very low (34 and 0.26 lmol/L, respectively).
Our results suggest that plasma selenium concentrations in our elderly participants were not low enough to affect thyroid function to any extent. In deficiency, selenium is well maintained in the thyroid gland, and the deiodinases are high on the hierarchy of selenoproteins, such that selenium status must be very low to modify activity of these enzymes (32, 33) . We saw no interaction between mild iodine deficiency and low selenium status in our subjects. The mean plasma selenium concentration of our elderly participants (1.20 lmol/L) was higher than in an earlier cohort of older New Zealand women (0.90 lmol/L) (14), a 1977 study of older adults (0.48 lmol/L) (34), and New Zealand adults (1.14 lmol/L) (10). We had expected the selenium status of our older adults to be lower than that of younger adults, as shown in several studies (27, 34, 35) , a likely result of low micronutrient intake in older adults (36, 37) . The higher than expected selenium status of our older participants reflects the trend of increasing selenium status among New Zealand residents (8, 38) . Whole-blood GPx activity increased along with plasma selenium concentration, indicating that GPx in our older population was suboptimal. However, the increase was smaller than observed in earlier studies (9, 19 ) (9% cf 12-15%), suggesting that activity of GPx is approaching maximal values as a person's selenium status increases.
The iodine status (MUIC, 48 lg/L) of our older New Zealand participants was indicative of mild-to-moderate iodine deficiency, which confirms recent observations of a re-emergence of iodine deficiency in New Zealand. This has resulted in signs of in the selenium plus iodine group (n = 20), but at week 12 MUICs of both groups were still indicative of mild iodine deficiency (,100 lg/L). Supplementation at a higher amount appears necessary to adequately improve iodine status. There are several possible reasons for the lack of significant change in iodine excretion of the selenium plus iodine group. Although analysis of the selenium plus iodine supplements showed they contained an average of 80 lg I, the variability was greater than for the iodine supplements, and 10 supplements chosen for analysis may not have been representative of all supplements consumed. Because of the greater variability, some participants may have received more supplements that did not contain the full complement of iodine. Alternatively, the increase may have been lower because baseline geometric mean UIC (62.8 lg/L) of the selenium plus iodine group was higher than the iodine group (33.4 lg/L). In addition, the small sample size of 20 people who gave a urine sample at week 12 may not have been sufficient to detect a significant change. Serum concentrations of TSH, free T 3 , and free T 4 of most participants fell within the manufacturers' reference ranges. However, the median thyroglobulin concentration of 15.8 lg/L was indicative of mild iodine deficiency (10.0-19.9 lg/L) (26), as was the MUIC. Cross-sectional studies have shown that high thyroglobulin concentrations are associated with low UICs (6, 40) , and thyroglobulin is considered the most sensitive indicator of iodine status. A decrease in its concentration in our participants suggests that thyroid hyperplasia was present, which may clinically manifest as increased thyroid volume or goiter (6) . Iodine supplementation alone significantly reduced thyroglobulin concentration (P = 0.009), whereas the decrease with selenium plus iodine supplementation was not significant after adjustment for change in the placebo group. Other studies in iodine-deficient populations have similarly shown thyroglobulin concentration to decrease with iodine prophylaxis (41, 42) . However, at week 12 the median thyroglobulin concentrations of the iodine group (12.0 lg/L) and the selenium plus iodine group (11.6 lg/L) were still indicative of mild iodine deficiency (26) , confirming that a supplement of 80 lg iodine was not sufficient to raise iodine status to be adequate for optimal thyroid hormone function.
In conclusion, we found little evidence of an improvement in thyroid function with selenium supplementation, apart from a nonsignificant increase in free T 3 concentrations. This suggests that selenium intake is adequate for thyroid function in New Zealand, although not for maximal GPx activity. However, our mild-to-moderate iodine deficiency appears to be compromising thyroid function, because MUICs and thyroglobulin concentrations have approached amounts that the WHO/UNICEF/ ICCIDD (20, 26) classify as a public health problem. Iodine supplementation improved thyroid function as shown by a decrease in thyroglobulin concentration; however, daily supplementation with 80 lg I for 12 wk was insufficient to attain adequate iodine or thyroid status in this population. Combined selenium and iodine supplementation did not significantly affect thyroid function, suggesting that in this population selenium was not acting synergistically with iodine to further exacerbate effects of low iodine status on thyroid function.
